PubMed · 3425463
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
G Russell-Jones, H de Aizpurua. 1987. Mucosal immunogens.. https://pubmed.ncbi.nlm.nih.gov/3425463/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
The present study was designed to determine the effect of eicosapentaenoic acid (EPA) on the susceptibility of tumor cells to treatments that kill the cells by lipid peroxidation. Using AH109A carcinoma, a rat liver cancer, we measured EPA content, levels of antioxidants, and degree of lipid peroxidation in tumor tissue and normal liver tissue after oral administration of EPA. In the control group treated with distilled water, EPA in tumor tissue was lower than in normal liver tissue, suggesting that its content of polyunsaturated fatty acids (the substrates for lipid peroxidation) was inherently low. Levels of antioxidants also tended to be lower in tumor tissue. EPA level increased in both tumor and normal tissues after oral administration of EPA. At the same time, glutathione peroxidase (GSH-Px) increased in normal tissue, whereas tumor tissue displayed no increase in antioxidants; instead GSH decreased. The EPA-induced change in balance between substrates for lipid peroxidation and antioxidants suggested that tumor tissue might become more susceptible to lipid peroxidation than normal liver tissue. In fact, hyperthermia treatment did enhance lipid peroxidation and antitumor action. Our results indicate that oral EPA specifically increases the susceptibility of liver tumor tissue to lipid peroxidation, and hence enhance the antitumor effect of hyperthermia and prolongs survival.
Anergy, or T cell unresponsiveness to antigen, is one mechanism of T cell tolerance. However, the signaling events that lead to immune tolerance are not well understood. A common assumption is that soluble antigens, such as food antigens, are poor immunogens and induce tolerance because they fail to upregulate co-stimulatory molecules on the professional APC. Engagement of CD40 through a stimulatory antibody causes the upregulation of these costimulatory molecules. Using a CD4+ T cell adoptive transfer model specific to ovalbumin (OVA), we show that after upregulation of CD86 on APC through CD40 stimulation in vivo, T cells from OVA-fed mice remain refractory to proliferation, interleukin (IL)-2 and interferon (IFN)-gamma production. We conclude that upregulation of CD86 alone does not inhibit oral tolerance induction of CD4+ T cells, indicating that additional signals are involved in the decision process for CD4+ T cells to commit to tolerance versus sensitization. Our data challenge the belief that reconstitution of a costimulatory signal in the presence of soluble antigen is sufficient to override T cell tolerance and anergy.
D-methylphenidate is an enantiomer of D,L-methylphenidate and was developed as an improved treatment for attention deficit hyperactivity disorder in children. The current study was performed to determine and compare the toxicity of 2-50 mg/kg per day D-MPH and 100 mg/kg per day D,L-MPH for 90 days in rats with the top D-MPH dose being equimolar to 100 mg/kg D,L-MPH. The top D-MPH and D,L-MPH doses were at least 67 times that of the human dose and produced systemic exposures that were over 10 times higher than those typically achieved in children. During the course of the study, one male each from the 50 mg/kg per day and D,L-MPH groups and one female from the 50 mg/kg group died. Incidences of material around nose/eyes, scabbing, foot swelling, alopecia and abrasions were evident at 50 mg/kg per day D-MPH and 100 mg/kg per day D,L-MPH doses. Body weight and its changes decreased in a dose-dependent manner for D-MPH males. There were significant changes in some clinical chemistry measurements at the terminal bleed in the high dose groups of both sexes although most of these changes were resolved by the recovery bleed. Differences in absolute and relative body and certain organ weights for high dose D-MPH and D,L-MPH groups were seen at terminal necropsy with the differences no longer present after the recovery period. No abnormal or gross histopathological changes were associated with any of these organ weight changes reported for the terminal and recovery periods. Based on body weight changes, the no observed adverse effect level for D-MPH in rats was 20 mg/kg. Overall, the toxicity profile observed in rats with 50 mg/kg per day D-MPH was comparable to that of an equimolar dose of D,L-MPH (100 mg/kg per day) when given repeatedly for 90 days using a twice a day dosing regimen.